Research and Markets: Remicade, Enbrel, Humira and Avonex Are the Leading Drugs in the Autoimmune Field.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36922) has announced the addition of Biotech in Autoimmune and Inflammatory Disease 2006, 2nd Edition to their offering.

The value of biological drugs indicated for autoimmune diseases, which affect up to 5% of the total world population, was roughly $11 billion in 2005. Remicade, Enbrel, Humira and Avonex currently lead the autoimmune field. These drugs are transforming the treatment of autoimmune diseases. In addition, novel therapies for psoriasis, asthma, and lupus will in the near future add tremendous revenue to an already rapidly growing field.

Medical, pharmaceutical and biotechnological advances are increasingly supporting the use of biological drugs in the treatment of autoimmune and inflammatory diseases. Indeed, biologics are having a major impact on the treatment of those diseases for which there has been significant unmet need for decades. As the new drugs are capable of targeting disease-causing proteins in a more specific fashion, while also carrying lower risks of adverse side effects, they have considerable advantages over traditional treatments.

Given the above advantages, coupled with more commercial interest, better understanding of disease causes and higher levels of patient familiarity with the new medicines, biologics will continue to undermine the market share of traditional drugs.

This report assesses the current and future position of biologics in the fields of multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis and asthma.

Key Features of This Report:

--Thorough financial breakdown of the leading products and companies making an impact in autoimmune disease therapy

--Market analysis and differentiation of biotech vs. synthetic drugs in combatting autoimmune diseases

Financial forecasts for key autoimmune disease therapies as well as overall disease category value through 2010

--Integrative discussion of clinical data and key trials for already marketed as well as emerging biologics

--Identification and discussion of trends and issues that will have a significant impact on the future of biotech drug sales in the autoimmune market

--Appraisal of development status for key biotech drugs being developed for various autoimmune diseases and discussion of research trends

Who Should Buy This Report:

--Companies interested in understanding the wider opportunities and challenges in the autoimmune and inflammatory disease markets

--Pharma/biotech companies wishing to identify opportunities and threats to products in these markets in order to examine a variety of profit maximization strategies

--Companies interested in understanding the state of R&D in relation to multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis and asthma

Topics Covered

1 Methodology and Executive Summary

2 An Introduction to Autoimmune Diseases

3 Multiple Sclerosis

4 Rheumatoid Arthritis

5 Systemic Lupus Erythematosus (SLE)

6 Inflammatory Bowel Disease

7 Psoriasis

8 Asthma

Tables

Graphs

Diagrams

Druge Mentioned Include:

- Avonex - Betaseron - Rebif - Copaxone - Novantrone - ABT 874 - Rituxan - Campath - Zenapax - MLN1202 - Remicade - Enbrel - Kineret - Orencia - Rituxan - Remicade - Enbrel - Humira - Orencia - Rituxan - CDP-870 - Actemra - AMG 714 - Eculizumab - IDEC-151 - AMG 719 - TAK 715 - Golimumab - Denosumab - Pegsunercept - SCIO 469 - BMS 561392 - Belimumab - Neumega - Belatacept - VX 702 - Denileukin - Riquent - Rituxan - LymphoStat-B - ETI-201 - AMG 412 - AMG 623 - Abatacept - TACI-lg - Actemra - TRX-1 - TV-4710 - Prestara - CellCept - Linomide - Humira - Kremezin - Neumega - Tetomilast - CDP-870 - Tysabri - Prograf - Leukine - Alicaforsen - MLN-02 - Rebif - RDP58

For more information visit http://www.researchandmarkets.com/reports/c36922